The digoxin-propafenone interaction: Characterization of a mechanism using renal tubular cell monolayers

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 39-45

  Woodland, Cindy ^a,d   Verjee, Zul ^b,c   Giesbrecht, Esther ^b,c   Koren, Gideon ^a,c,d   Ito, Shinya ^a,b,c,d  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYPROPAFENONE; DEPROPYLPROPAFENONE; DIGOXIN; DRUG METABOLITE; GLYCOPROTEIN P; PROPAFENONE; VINBLASTINE;

ANIMAL CELL; ARTICLE; BASOLATERAL MEMBRANE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG TRANSPORT; KIDNEY TUBULE CELL; KIDNEY TUBULE EXCRETION; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DIGOXIN; DOGS; DRUG INTERACTIONS; FEMALE; KIDNEY TUBULES; P-GLYCOPROTEIN; PROPAFENONE; VINBLASTINE;

EID: 0030868579     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. AGÚNDEZ, J. A. G., LEDESMA, M. C., LADERO, J. M. AND BENÍTEZ, J.: Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 57: 265-269, 1995.
2. BELZ, G. G., DOERING, W., MUNKES, R. AND MATTHEWS, J.: Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin. Pharmacol. Ther. 33: 410-417, 1983.
3. BERTILSSON, L.: Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29: 192-209, 1995.
4. BOTSCH, S., GAUTHIER, J.-C., BEAUNE, P., EICHELBAUM, M. AND KROEMER, H. K.: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 43: 120-126, 1993.
5. BRADLEY, G., JURANKA, P. F. AND LING, V.: Mechanism of multidrug resistance. Biochim. Biophys. Acta 948: 87-128, 1988.
6. CALVO, M. V., MARTIN-SUAREZ, A., MARTIN LUENGO, C., AVILA, C., CASCON, M. AND HURLÉ, A. D.-G.: Interaction between digoxin and propafenone. Ther. Drug. Monit. 11: 10-15, 1989.
7. DE LANNOY, I. A. M. AND SILVERMAN, M.: The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189: 551-557, 1992.
8. FUNCK-BRENTANO, C., KROEMER, H. K., LEE, J. T. AND RODEN, D. M.: Propafenone. N. Engl. J. Med. 322: 518-525, 1990.
9. HAEFELI, E. W., VOZEH, S., HA, H.-R. AND FOLLATH, F.: Comparison of the pharmacodynamic effects of intravenous and oral propafenone. Clin. Pharmacol. Ther. 48: 245-254, 1990.
10. HEDMAN, A., ANGELIN, B., ARVIDSSON, A., DAHLQVIST, R. AND NILSSON, B.: Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine. Clin. Pharmacol. Ther. 47: 20-26, 1990.
11. HOLLMANN, M., BRODE, E., HOTZ, D., KAUMEIER, S. AND KEHRHAHN, O. H.: Investigations on the pharmacokinetics of propafenone in man. Arzneimittel-Forschung 33: 763-770, 1983.
12. HORIO, M., CHIN, K. V., CURRIER, S. J., GOLDENBERG, S., WILLIAMS, C., PASTAN, I., GOTTESMAN, M. M. AND HANDLER, J.: Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem. 264: 14880-14884, 1989.
13. m of the pump. Biochim. Biophys. Acta 1027: 116-122, 1990.
14. +-gradient-dependent active transport of tetraethylammonium cation in apical-membrane vesicles isolated from kidney epithelial cell line LLC-PK1. Biochem. J. 227: 199-203, 1985.
15. ITO, S., KOREN, G., HARPER, P. A. AND SILVERMAN, M.: Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1). Can. J. Physiol. Pharmacol. 71: 40-47, 1993a.
16. ITO, S., WOODLAND, C., HARPER, P. A. AND KOREN, G.: P-glycoprotein-mediated renal tubular secretion of digoxin. Life Sci. 53: 25-31, 1993b.
17. ITO, S., WOODLAND, C., HARPER, P. A. AND KOREN, G.: The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). Life Sci. 53: PL399-PL403, 1993c.
18. ITO, S., WOODLAND, C. AND KOREN, G.: Modeling of cellular digoxin transport. Pharmacologist 39: 114, 1997.
19. KATES, R. E., YEE, Y. G. AND WINKLE, R. A.: Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin. Pharmacol. Ther. 37: 610-614, 1985.
20. KROEMER, H. K., FUNCK-BRENTANO, C., SILBERSTEIN, D. J., WOOD, A. J. J., EICHELBAUM, M., WOOSLEY, R. L. AND RODEN, D. M.: Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 79: 1068-1076, 1989.
21. SCHINKEL, A. H., WAGENAAR, E., VAN DEEMTER, L., MOL, C. A. A. M. AND BORST, P.: Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96: 1698-1705, 1995.
22. SEIPEL, L. AND BREITHARDT, G.: Propafenone: A new anti-arrhythmic drug. Eur. Heart J. 1: 309-313, 1980.
23. SIDDOWAY, L. A., THOMPSON, K. A., MCALLISTER, C. B., WANG, T., WILKINSON, G. R., RODEN, D. M. AND WOOSLEY, R. L.: Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. Circulation 75: 785-791, 1987.
24. STEINESS, E.: Renal tubular secretion of digoxin. Circulation 50: 103-107, 1974.
25. TANIGAWARA, Y., OKAMURA, N., HIRAI, M., YASUHARA, M., UEDA, K., KIOKA, N., KOMANO, T. AND HORI, R.: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263: 840-845, 1992.
26. THIEBAUT, F., TSURUO, T., HAMADA, H., GOTTESMAN, M. M., PASTAN, I. AND WILLINGHAM, M. C.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84: 7735-7738, 1987.
27. VERJEE, Z. AND GIESBRECHT, E.: An HPLC method for the quantitation of propafenone and its metabolites in pediatric samples. In Recent Developments in Therapeutic Drug Monitoring and Clinical Toxicology, pp. 383-388, Marcel Dekker, New York, NY, 1992.